Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Platelet membrane coated resiquimod nanoparticles - Cello Therapeutics

Drug Profile

Platelet membrane coated resiquimod nanoparticles - Cello Therapeutics

Alternative Names: CE-120; PNP-R848

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cello Therapeutics
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
  • Mechanism of Action Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jan 2024 Phase-I clinical trials in Solid tumours in USA (Intratumoural) prior to January 2024 (Cello Therapeutics pipeline, January 2024)
  • 14 May 2021 Cello Therapeutics has patent protection for the platelet-membrane coated nanoparticle technology platform in several countries worldwide, including Hong Kong, China, US, Canada, Japan, Taiwan, Europe, and PCT application (Cello Therapeutics website, May 2021).
  • 14 May 2021 Cello Therapeutics plans to file IND application for Solid tumours (Cello Therapeutics pipeline, May 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top